Fennec Pharmaceuticals
FENC
13 hedge funds and large institutions have $57.7M invested in Fennec Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
33.07% more ownership
Funds ownership: 0% → 33.07% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Southpoint Capital Advisors
New York
|
+$46.4M |
| 2 |
6CM
683 Capital Management
New York
|
+$9.39M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.9M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$774K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$576K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCA
1
Southpoint Capital Advisors
New York
| $44.3M | +$46.4M | +3,997,214 | New |
|
|
6CM
2
683 Capital Management
New York
| $8.87M | +$9.39M | +808,365 | New |
|
|
ACP
3
Acuta Capital Partners
Redwood City,
California
| $2.77M | +$2.9M | +250,000 | New |
|
|
ACA
4
Avoro Capital Advisors
New York
| $731K | +$774K | +66,666 | New |
|
|
GIM
5
Granahan Investment Management
Waltham,
Massachusetts
| $550K | +$576K | +49,593 | New |
|
|
USAA
6
United Services Automobile Association
San Antonio,
Texas
| $456K | +$478K | +41,140 | New |
|
|
HFM
7
Hartford Financial Management
Hartford,
Connecticut
| $12K | +$13.4K | +1,150 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $4K | +$4.64K | +400 | New |
|
9
UBS Group
Zurich,
Switzerland
| $1K | +$917 | +79 | New |
|
|
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $43 | +$46 | +4 | New |
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$58 | +5 | New |
|
12
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$70 | +6 | New |
|
13
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$209 | +18 | New |
|
FENC Hedge Fund Activity: Q3 2017 in Review
13 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2017, worth a combined $57.7M.
Buyers outnumbered sellers: 13 funds opened new FENC positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Southpoint Capital Advisors, opening a new position worth an estimated $46.4M.
- 13 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2017, up from 0 in Q2 2017.
- Funds reported $57.7M of Fennec Pharmaceuticals stock for Q3 2017.
- 13 funds opened new Fennec Pharmaceuticals positions in Q3 2017 and 0 closed out, a net change of +13 holders.
- The largest Fennec Pharmaceuticals buyer in Q3 2017 was Southpoint Capital Advisors, an estimated $46.4M added.
Based on aggregated 13F filings for Q3 2017.